TY - JOUR
T1 - Immune Checkpoint Inhibitors
T2 - Anti-NKG2A Antibodies on Board
AU - Mingari, Maria Cristina
AU - Pietra, Gabriella
AU - Moretta, Lorenzo
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
AB - Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
UR - http://www.scopus.com/inward/record.url?scp=85059231900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059231900&partnerID=8YFLogxK
U2 - 10.1016/j.it.2018.12.009
DO - 10.1016/j.it.2018.12.009
M3 - Short survey
AN - SCOPUS:85059231900
SN - 1471-4906
VL - 40
SP - 83
EP - 85
JO - Trends in Immunology
JF - Trends in Immunology
IS - 2
ER -